Bullish & Foolish
Full GNLX fundamentals All 466 on the Survival Watch

GNLXGENELUX CORPORATION

Is Genelux struggling financially?

Yes, by its own account. Genelux told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$123.1M
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 7months

    If the burn speeds up

    Empty by Jan 2027

  • 10months

    If it eases off

    Empty by Apr 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$18.7M

÷

Cash burned over the last 12 months

$26.4M

What Genelux told the SEC

…and incurred a net loss of $ 8.9 million and cash used in operations of $ 6.1 million during the three months ended March 31, 2026. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025 financial statements, has expressed substantial doubt about…

GENELUX CORPORATION, Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 22.6% share-count increase The company issued stock. Each share now owns 18.4% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 34% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt